Phase II Study of induction Carboplatin+Paclitaxel+Bevacizumab combination therapy for stage III Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- on-Squamous Non-Small-Cell Lung Cancer
- Registration Number
- JPRN-UMIN000004327
- Lead Sponsor
- The Tokyo Cooperative Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Not provided
1)History of active double cancer within 5 years 2)Overt infection 3)History of hemoptysis 4)With great vessel invasion 5)Cavity in tumor 6)Receiving anticoagulant drug(except Aspirin within 324mg/day) 7)Uncontrollable Gastrointestinal ulceration 8)Current or previous(within the last 1 year)history of GI perforation 9)Severe cardiac disease 10)History of Arterial thromboembolism within 1year 11)Interstitial pneumonia or pulmonary fibrosis detectable on X-ray 12)Peripheral neuropathy > Grade2 13)Major surgical procedure 14)With a history of drug sensitivity 15)History of pregnancy or lactation 16)No intention to practice birth control 17)Patients whose participation in the trial is judged to be inappropriate by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method